Abstracts tagged "Lupus"

Abstract Number: 2126 • 2018 ACR/ARHP Annual Meeting
STAT4 Activation By Type I Interferons Regulates Pathogenic IL-21 and IFN-γ in Lupus
Xuemei Dong¹, Fotios Koumpouras², Joseph E. Craft³ and Jason Weinstein¹, ¹Rheumatology, Yale University School of Medicine, New Haven, CT, ²Internal Medicine, Rheumatology, Yale University School of Medicine, New Haven, CT, ³Department of Internal Medicine/Rheumatology, Yale University School of Medicine, New Haven, CT
Background/Purpose: Follicular helper T cells (Tfh) cells in lupus help shape the germinal center (GC) response by delivering contact-dependent and soluble signals, including the cytokines…
Abstract Number: 2851 • 2018 ACR/ARHP Annual Meeting
NF-Κappa b Signaling in the Myeloid Cell Lineage Drives the Pathogenesis of Immune-Mediated Nephritis
Samantha Chalmers¹, Sayra Garcia¹, Justine Shum¹, Leal Herlitz² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Cleveland Clinic, Cleveland, OH, ³Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY
Background/Purpose: Immune-mediated glomerulonephritis is a serious end organ pathology that commonly affects patients with systemic lupus erythematosus (SLE). Nephrotoxic serum nephritis, induced by passive transfer…
Abstract Number: 473 • 2018 ACR/ARHP Annual Meeting
A Weighty Diagnosis: Weight Change and Risk Factors in Early Juvenile Systemic Lupus Erythematosus
Erin Treemarcki¹, Jackie Szymonifka², Alexa Adams³, Nancy Pan⁴, Sarah Taber⁵ and Karen Onel⁵, ¹Hospital for Special Surgery Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁴Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, ⁵Pediatric Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, NY
Background/Purpose: SLE is a chronic, multisystem autoimmune condition with multiple comorbidities due to inflammation and treatment, including metabolic syndrome, poor cardiac outcome, and poor quality…
Abstract Number: 766 • 2018 ACR/ARHP Annual Meeting
Neutrophil Extracellular Traps Are a Source of Extracellular High Mobility Group Box-1: Association with Clinical and Histopathological Features in Patients with Lupus Nephritis
Laura Patricia Whittall¹, Diana Gómez-Martín¹, Jiram Torres-Ruíz², Alejandro Zentella Dehesa¹, Miguel Tapia-Rodríguez¹ and Jorge Alcocer-Varela¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición, Salvador Zubirán, Mexico City, Mexico
Background/Purpose: Current evidence suggests that neutrophils play an important role in the pathophysiology of lupus nephritis (LN) mainly through the secretion of type I IFN…
Abstract Number: 1871 • 2018 ACR/ARHP Annual Meeting
A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE
Maureen A. McMahon¹, Jennifer M. Grossman², Lori Sahakian³, Christina Charles-Schoeman⁴, John Fitzgerald¹, Mihaela Taylor⁴, Alan Gorn¹, Eloise Olmos¹, Daniel J. Wallace⁵, Bevra H Hahn^1,4 and Brian Skaggs⁴, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA, ⁴Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ⁵Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory…
Abstract Number: 2129 • 2018 ACR/ARHP Annual Meeting
Precipitating Anti-dsDNA Peptide Repertoires in Lupus
Jing Jing Wang¹, Alexander Colella¹, Dimitra Beroukas², Tim Chataway³ and Tom Gordon^1,4, ¹Immunology, Flinders University, Adelaide, Australia, ²Immunology, SA Pathology, Adelaide, AR, Australia, ³Proteomic Facility, Flinders University, Adelaide, Australia, ⁴Immunology, SA Pathology, Adelaide, Australia
Background/Purpose: Anti-double-stranded (ds)DNA autoantibodies are prototypic serological markers of systemic lupus erythematosus (SLE) but little is known about their immunoglobulin variable (IgV) region composition at…
Abstract Number: 2892 • 2018 ACR/ARHP Annual Meeting
Safety and Immune Response of a Live Attenuated Herpes Zoster Vaccine in Patients with Systemic Lupus Erythematosus (SLE): A Randomized Placebo-Controlled Trial
Chi Chiu Mok¹, Kwok Hung Chan², Ling Yin Ho³ and Patrick Chiu Yat Woo², ¹Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ²Microbiology, University of Hong Kong, Hong Kong, Hong Kong, ³Dept of Medicine, Tuen Mun Hospital, Hong Kong SAR, Hong Kong
Background/Purpose: To evaluate the safety and immune response of a live attenuated herpes zoster (HZ) vaccine in patients with SLE by a randomized placebo-control trial…
Abstract Number: 474 • 2018 ACR/ARHP Annual Meeting
Lupus Impact Tracker (LIT) As a New Tool in Assessing Patient Reported Outcome in Pediatric Lupus
Suhas Ganguli¹, Joyce Hui-Yuen¹, Meenakshi Jolly^2,3, Jane Cerise⁴ and B. Anne Eberhard⁵, ¹Pediatric Rheumatology, Cohen Children's Medical Center, Lake Success, NY, ²Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Biostatistics, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Pediatric Rheumatology, Cohen Children's Medical Center, New Hyde Park, NY
Background/Purpose: Patient Reported Outcome (PRO) measures for Quality of Life (QoL) in patients with lupus are useful supplements to the physician-derived indices of disease activity…
Abstract Number: 939 • 2018 ACR/ARHP Annual Meeting
Rab4A Protects from Lupus Nephritis By Limiting Germinal Center Formation and Pro-Inflammatory Expression of GLUT1 and Integrin By Renal Epithelial Cells
Gourav Choudhary¹, Nick Huang², Ryan Kelly³, Thomas Winans⁴, Manuel Duarte², Mark Haas⁵ and Andras Perl², ¹Department of Biochemistry and Mol. Biology, SUNY Upstate Medical University, Syracuse, NY, ²Medicine, SUNY Upstate Medical University, Syracuse, NY, ³SUNY, Syracuse, NY, ⁴SUNY Upstate Medical University, Syracuse, NY, ⁵Professor of Pathology, Cedars-Sinai, Los Angeles, CA
Background/Purpose: Lupus nephritis is most common cause of mortality and morbidity in systemic lupus erythematosus (SLE) patients and 60% of SLE patients develops lupus nephritis.…
Abstract Number: 1874 • 2018 ACR/ARHP Annual Meeting
Remission and Low Disease Activity State Are Protective of Intermediate and Long-Term Outcomes in SLE Patients. Data from a Multi-Ethnic, Multi-Center US Cohort
Guillermo J. Pons-Estel^1,2, Graciela S. Alarcón³, Manuel Ugarte-Gil^4,5, Luis M. Vilá⁶, John D. Reveille⁷ and Gerald McGwin³, ¹Rheumatology, Hospital Provincial de Rosario, Rosario, Argentina, ²Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario. Argentina, Rosario, Argentina, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology, Universidad Científica del Sur, Lima, Peru, ⁵Hospital Guillermo Almenara Irigoyen. EsSalud, Lima, Peru, ⁶Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, Puerto Rico, ⁷McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX
Background/Purpose: Over the last few years the importance of treating patients with SLE towards achieving either Remission or LDAS (Treat-to-Target approach) has become evident. We…
Abstract Number: 2330 • 2018 ACR/ARHP Annual Meeting
Vitamin D and Bisphosphonate Therapy in SLE Patients Who Receive Glucocorticoids: Are We Offering the Best Care?
Smarika Sapkota¹, Sara Baig², Toy Hess³, Ann Marie O'Connell⁴, Jeremiah Menk³, Parastoo Fazeli⁵ and Anna K. Shmagel⁶, ¹Division of General Internal Medicine, University of Minnesota, Minneapolis, MN, ²Department of Internal Medicine, University of Minnesota, Minneapolis, MN, ³University of Minnesota, Minneapolis, MN, ⁴University of Minnesota, Minnepolis, MN, ⁵Rheumatology, University of Minnesota, Minneapolis, MN, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN
Background/Purpose: Glucocorticoids(GC) are frequently used for the treatment of systemic lupus erythematosus (SLE), and glucocorticoid induced osteoporosis (GIOP) is a well-known complication of long term…
Abstract Number: 2946 • 2018 ACR/ARHP Annual Meeting
T Peripheral Helper Cells Are Expanded in the Circulation of Active SLE Patients and Correlate with CD21low B Cells
Deepak Rao¹, Alexandra Bocharnikov², Chamith Fonseka³, Joshua Keegan², Betty Diamond⁴, Jennifer Anolik⁵, Peter Nigrovic¹, Soumya Raychaudhuri^3,6, James A. Lederer⁷ and Michael Brenner⁸, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Divisions of Genetics and Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Autoimmune Musculoskeletal and Hematopoietic Diseases, The Feinstein Institute for Medical Research, Manhasset, NY, ⁵Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁶Program in Medical and Population Genetics, Broad Institute of Massachusetts Technical Institute, Harvard University, Cambridge, MA, ⁷Department of Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁸Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Pathologic T cell-B cell interactions and production of autoantibodies are hallmark features of SLE. T follicular helper (Tfh) cells are generally considered the principal…
Abstract Number: PP09 • 2018 ACR/ARHP Annual Meeting
Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine
Marisa Zeppieri-Caruana, Lupus Chick, New York, NY
Background/Diagnosis: Like most people who live with a chronic illness and/or autoimmune disease, my story started long before I realized. Symptoms came and went throughout…
Abstract Number: 712 • 2018 ACR/ARHP Annual Meeting
Higher Prednisolone Dose during Treatment of Tuberculosis Correlates with Mortality during Tuberculosis Treatment in Systemic Lupus Erythematosus Patients: A Retrospective Cohort Study
Chiao-Feng Cheng, Cheng-Hsun Lu, Song-Chou Hsieh and Ko-Jen Li, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Tuberculosis (TB) has complex interplay with systemic lupus erythematosus (SLE). In addition, SLE, corticosteroid, and immunosuppressants are associated with TB infection. However, the prognostic…
Abstract Number: 972 • 2018 ACR/ARHP Annual Meeting
An Anti-CD28 Domain Antibody, Lulizumab, in Systemic Lupus Erythematosus: Results of a Phase II Study
Joan T. Merrill¹, Diane E. Shevell², Dominique Duchesne², Miroslawa Nowak², Sudeep Kundu², Ihab G. Girgis², Yanhua Sarah Hu², Steven G. Nadler³, Subhashis Banerjee² and John Throup², ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Bristol-Myers Squibb, Princeton, NJ, ³Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The T cell costimulatory molecule, CD28, is critical for the activation of pathogenic T cells in autoimmune diseases.1,2 An anti-CD28 domain antagonist antibody, lulizumab…

« Previous Page
1
…
6
7
8
9
10
…
31
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].